CureVac N.V. announced its financial results for the second quarter and first half of 2025, reporting a cash and cash equivalents position of €392.7 million as of June 30, 2025. The company reaffirmed its expected cash runway into 2028, indicating continued financial stability.
The company confirmed it entered into a definitive Purchase Agreement for BioNTech to acquire all shares of CureVac, aiming to unite the two German companies for mRNA-based treatments. Agreements were also made to resolve and dismiss all pending patent litigation in the U.S. with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, with a framework for resolving international disputes upon the acquisition's closing.
CureVac received Clinical Trial Application (CTA) clearance from the European Medicines Agency (EMA) for CVHNLC, its off-the-shelf cancer immunotherapy candidate for squamous non-small cell lung cancer. Data from Part B of the Phase 1 CVGBM glioblastoma study remain on track for the second half of 2025, demonstrating ongoing pipeline progress.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.